Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Geranium wilfordii extract (GWE) is a natural product derived from the traditional Chinese medicinal herb *Geranium wilfordii Maxim*, also known as Herba Geranii or lao-guan-cao. This ethanolic extract contains a variety of bioactive compounds, including geraniin, corilagin, gallic acid, quercetin, and 1,2,3,6-tetra-O-galloyl-β-D-glucose. GWE exhibits a broad range of pharmacological activities, including anti-inflammatory, immunomodulatory, antiviral, and antibacterial effects. Mechanistically, it has been identified as an inhibitor of tumor necrosis factor-alpha (TNF-α) and has been shown to modulate key signaling hub genes such as NOTCH2, HDAC2, and MAPK1. Research suggests its potential therapeutic utility in treating chronic inflammatory diseases like asthma, rheumatoid arthritis, and gout, as well as viral infections such as HSV-2 and various gastrointestinal disorders. It is currently utilized primarily as a research compound and in traditional medicine contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on geranium wilfordii extract.